A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 2/8/2015 |
| Start Date: | October 2014 |
| End Date: | April 2015 |
| Contact: | Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email: |
| Email: | Clinical.Trials@bms.com |
A Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects
This is the first clinical study with the BMS-986147 compound in healthy subjects. The
purpose of this study is to guide the dose range and dose frequency for future studies with
BMS-986147 and will provide guidelines for selection of a potentially effective dose in
patients.
purpose of this study is to guide the dose range and dose frequency for future studies with
BMS-986147 and will provide guidelines for selection of a potentially effective dose in
patients.
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com
Inclusion Criteria:
- Healthy men and women, ages 18 to 45 years
- Subjects must not have clinically significant deviation from normal: medical
history, physical examination, ECGs and laboratory evaluations
- Women of child bearing potential are eligible for enrollment.
- Women must have a negative pregnancy test
Exclusion Criteria:
- Evidence of organ dysfunction
- Any significant acute or chronic medical illness
- Inability to: tolerate oral medications, be venipunctured
We found this trial at
1
site
Click here to add this to my saved trials
